Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626478 · ClinicalTrials.gov registry record · Phase 4
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
A Phase 4 study, sponsored by Nicole Fram M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT05626478 is a Phase 4 study that has completed, run by Nicole Fram M.D.. The registered enrollment target is 50 participants.
The verdict
NCT05626478, a Phase 4 study, has completed, sponsored by Nicole Fram M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
Interventions
- DRUG Prednisolone Acetate 1% Oph Susp
- DRUG Dextenza 0.4Mg Ophthalmic Insert
- DRUG Prolensa 0.07% Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05626478
The ClinicalTrials.gov registry entry for NCT05626478 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nicole Fram M.D., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisolone Acetate 1% Oph Susp is the first listed.
NCT05626478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05626478 about?
NCT05626478 is a clinical study titled "Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery". Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
What is the current status of trial NCT05626478?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2023-06-01. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT05626478?
The interventions under investigation include: Prednisolone Acetate 1% Oph Susp (DRUG), Dextenza 0.4Mg Ophthalmic Insert (DRUG), Prolensa 0.07% Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT05626478?
This trial is sponsored by Nicole Fram M.D., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.